Kewen Hu

1.2k total citations · 1 hit paper
12 papers, 913 citations indexed

About

Kewen Hu is a scholar working on Molecular Biology, Oncology and Biomedical Engineering. According to data from OpenAlex, Kewen Hu has authored 12 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Oncology and 3 papers in Biomedical Engineering. Recurrent topics in Kewen Hu's work include Nanoplatforms for cancer theranostics (3 papers), Extracellular vesicles in disease (2 papers) and Protein Tyrosine Phosphatases (2 papers). Kewen Hu is often cited by papers focused on Nanoplatforms for cancer theranostics (3 papers), Extracellular vesicles in disease (2 papers) and Protein Tyrosine Phosphatases (2 papers). Kewen Hu collaborates with scholars based in China, United States and Netherlands. Kewen Hu's co-authors include Xiufeng Pang, Mingyao Liu, Wenhao Jiang, Qiang Zhang, Zhengjie Zhou, Yiyun Cheng, Kun Li, Jieqiong Wang, Feixiong Cheng and Jing Lv and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Biomaterials.

In The Last Decade

Kewen Hu

12 papers receiving 908 citations

Hit Papers

Suppression of the SLC7A11/glutathione axis causes synthe... 2019 2026 2021 2023 2019 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma
    2019 287 citations Kewen Hu, Kun Li et al. Journal of Clinical Investigation profile →

Peers

Kewen Hu
Meysam Yousefi Iran
Zhi Hu China
Yan Du China
Wen‐Pin Su Taiwan
Vegi M. Naidu Germany
Jinlu Ma China
Yiping Qu China
Yan Hu China
Wenchu Lin China
Chong Ma China
Meysam Yousefi Iran
Kewen Hu
Citations per year, relative to Kewen Hu Kewen Hu (= 1×) peers Meysam Yousefi

Countries citing papers authored by Kewen Hu

Since Specialization
Citations

This map shows the geographic impact of Kewen Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kewen Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kewen Hu more than expected).

Fields of papers citing papers by Kewen Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kewen Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kewen Hu. The network helps show where Kewen Hu may publish in the future.

Co-authorship network of co-authors of Kewen Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Kewen Hu. A scholar is included among the top collaborators of Kewen Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kewen Hu. Kewen Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Li, Na, Xiaochen Lu, Midie Xu, et al.. (2023). Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression. Nature Metabolism. 5(7). 1159–1173. 50 indexed citations
2.
Lu, Yue, Kewen Hu, Yunpeng Zhang, et al.. (2022). Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer. Acta Pharmaceutica Sinica B. 13(3). 1145–1163. 23 indexed citations
3.
Li, Kun, Yanan Liu, Yi� Ding, et al.. (2022). BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer. Journal of Clinical Investigation. 132(22). 24 indexed citations
4.
Jiang, Wenhao, Yanan Liu, Wanfeng Huang, et al.. (2020). Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer. Biochemical Pharmacology. 177. 113960–113960. 18 indexed citations
5.
Gao, Na, Jiwei Chen, Lingling Fan, et al.. (2020). ERK/MAPK signaling is essential for intestinal development through Wnt pathway modulation. Development. 147(17). 22 indexed citations
6.
Hu, Kewen, Kun Li, Jing Lv, et al.. (2019). Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. Journal of Clinical Investigation. 130(4). 1752–1766. 287 indexed citations breakdown →
7.
Zhou, Zhengjie, Kewen Hu, Yuan Zou, et al.. (2017). Autophagy inhibition enabled efficient photothermal therapy at a mild temperature. Biomaterials. 141. 116–124. 167 indexed citations
8.
Guan, Yuting, Yanlin Ma, Qi Li, et al.. (2016). CRISPR /Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Molecular Medicine. 8(5). 477–488. 131 indexed citations
9.
Wang, Jieqiong, Kewen Hu, Jiawei Guo, et al.. (2016). Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nature Communications. 7(1). 11363–11363. 80 indexed citations
10.
Zhou, Zhengjie, Kewen Hu, Yan Yang, et al.. (2016). Cancer Therapy: Dendritic Platinum–Copper Alloy Nanoparticles as Theranostic Agents for Multimodal Imaging and Combined Chemophotothermal Therapy (Adv. Funct. Mater. 33/2016). Advanced Functional Materials. 26(33). 5950–5950. 2 indexed citations
11.
Li, Kun, Qunfeng Guo, Jun Yang, et al.. (2016). FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. Oncotarget. 8(3). 5048–5056. 45 indexed citations
12.
Zhou, Zhengjie, Kewen Hu, Yan Yang, et al.. (2016). Dendritic Platinum–Copper Alloy Nanoparticles as Theranostic Agents for Multimodal Imaging and Combined Chemophotothermal Therapy. Advanced Functional Materials. 26(33). 5971–5978. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meysam Yousefi Breakdown of academic impact, for papers by Zhi Hu Breakdown of academic impact, for papers by Yan Du Breakdown of academic impact, for papers by Wen‐Pin Su Breakdown of academic impact, for papers by Vegi M. Naidu Breakdown of academic impact, for papers by Jinlu Ma Breakdown of academic impact, for papers by Yiping Qu Breakdown of academic impact, for papers by Yan Hu Breakdown of academic impact, for papers by Wenchu Lin Breakdown of academic impact, for papers by Chong Ma
Rankless by CCL
2026